Core Viewpoint - The announcement by Guangdong Tianen Pharmaceutical Co., Ltd. regarding the acceptance of the registration application for Lidocaine and Prilocaine aerosol marks a significant advancement in the research and commercialization of sexual health medications [1]. Group 1: Product Development - Tianen's subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., received the acceptance notice from the National Medical Products Administration for the aerosol product [1]. - The original drug was developed by Plethora Solutions in the UK and has been commercially promoted in major European markets since 2013, transitioning from prescription to over-the-counter status in 2020 [1]. Group 2: Product Advantages - The aerosol formulation offers advantages over oral medications like Dapoxetine, including ease of use, higher patient compliance, rapid onset of action, and reduced side effects associated with oral drugs [1]. - The product has been validated through over ten years of clinical use in overseas markets, confirming its efficacy and safety [1]. Group 3: Market Positioning - Tianen has a strong brand foundation and channel advantages in the sexual health sector, with its core product "Aiting Jiu" (Dapoxetine) having established a comprehensive sales network [1]. - The successful launch of the aerosol could leverage the brand effect and channel resources of the "Aiting Jiu" series to quickly penetrate the market and enhance the company's competitive position in the sexual health business [2].
利多卡因丙胺卡因气雾剂获受理 泰恩康加码两性健康领域